A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells

Kobayashi, Eiji; Kishi, Hiroyuki; Ozawa, Tatsuhiko; Hamana, Hiroshi; Nakagawa, Hidetoshi; Jin, Aishun; Lin, Zhezhu; Muraguchi, Atsushi

doi:10.1016/j.bbrc.2014.10.024

Cited by 34 publications

(29 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NK-92 обладают и недостатками -они латентно заражены EBV и достаточно сложны в культивации [173]. [75], линии HANK-1, KHYG-1, NK-YS, NKG, IMC-1 и SNK-6 [89].…”

Section: клеточная иммунотерапия в онкологииunclassified

Cellular Immunotherapy: A Modern Approach to Treatment of Oncological Diseases

Лежнин¹,

Христиченко²,

Ratnikova³

et al. 2018

Med. immunol.

View full text Add to dashboard Cite

Section: клеточная иммунотерапия в онкологииunclassified

Cellular Immunotherapy: A Modern Approach to Treatment of Oncological Diseases

Лежнин¹,

Христиченко²,

Ratnikova³

et al. 2018

Med. immunol.

View full text Add to dashboard Cite

“…It was found that the TR1-scFv-CARexpressing NK cell line and peripheral blood lymphocytes killed target cells via CAR signal- induced cytolytic activity in addition to TR1-induced apoptosis. 141 …”

Section: Recent Advances In Trail Therapies Designs and Potential Rolmentioning

confidence: 99%

Journey of TRAIL from bench to bedside and its potential role in immuno-oncology

Naoum¹,

Buchsbaum

Tawadros

et al. 2017

Oncol Rev

View full text Add to dashboard Cite

Induction of apoptosis in cancer cells has increasingly been the focus of many therapeutic approaches in oncology field. Since its identification as a TNF family member, TRAIL (TNF-related apoptosis-inducing ligand) paved a new path in apoptosis inducing cancer therapies. Its selective ability to activate extrinsic and intrinsic cell death pathways in cancer cells only, independently from p53 mutations responsible for conventional therapeutics resistance, spotted TRAIL as a potent cancer apoptotic agent. Many recombinant preparations of TRAIL and death receptor targeting monoclonal antibodies have been developed and being tested pre-clinically and clinically both as a single agent and in combinations. Of note, the monoclonal antibodies were not the only type of antibodies developed to target TRAIL receptors. Recent technology has brought forth several single chain variable domains (scFv) designs fused recombinantly to TRAIL as well. Also, it is becoming progressively more understandable that field of nanotechnology has revolutionized cancer diagnosis and therapy. The recent breakthroughs in materials science and protein engineering have helped considerably in strategically loading drugs into nanoparticles or conjugating drugs to their surface. In this review we aim to comprehensively highlight the molecular knowledge of TRAIL in the context of its pathway, receptors and resistance factors. We also aim to review the clinical trials that have been done using TRAIL based therapies and to review various scFv designs, the arsenal of nano-carriers and molecules available to selectively target tumor cells with TRAIL.

show abstract

“…Therefore, many agonistic monoclonal antibodies specific for TRAIL receptors induce apoptosis in multiple tumor cell types, but some TRAIL receptor-expressing tumor cells, including Jurkat T cells, are resistant to TRAIL receptor-specific monoclonal antibody-induced apoptosis. Kobayashi et al [31] constructed a chimeric antigen receptor (CAR) of a TRAIL-receptor 1-specific single chain variable fragment (scFv) antibody (TRAIL-receptor 1-scFv-CAR), which killed Jurkat T cells via TRAIL-receptor 1-mediated apoptosis.…”

Section: Fig 1 Schematic Representation Of the Role Of Tumor Necrosmentioning

confidence: 99%

The role of the TNF receptors and apoptosis inducing ligands in tumor growth

Minchenko¹,

Tsymbal²,

Minchenko³

et al. 2016

Ukr.Biochem.J.

View full text Add to dashboard Cite

Tumor necrosis factor (TNF) superfamily receptors and TNF apoptosis inducing ligands play an important role in the realization of TNF function and control tumor growth. The TNF-related pathways are controlled by endoplasmic reticulum stress signaling, which has a crucial role in the control of cell proliferation and tumor growth. Furthermore, the inhibition of IRE1 (inositol requiring enzyme-1), which is a central mediator of endoplasmic reticulum stress sand mainly responsible for cell proliferation and apoptosis, leads to suppression of tumor growth through specific changes in the expression of genes encoding transcription factors, tumor suppressors, angiogenesis and apoptosis related proteins, including TNF superfamily receptors and TNF apoptosis inducing ligands. Therefore, changes in the expression level of TNF-related genes encoding TNF superfamily receptors and apoptosis inducing ligands possibly reflect metabolic reprogramming of cancer cells upon inhibition of IRE1-mediated endoplasmic reticulum stress signaling and correlate with suppression of glioma cell proliferation.

show abstract

A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells

Cited by 34 publications

References 22 publications

Cellular Immunotherapy: A Modern Approach to Treatment of Oncological Diseases

Cellular Immunotherapy: A Modern Approach to Treatment of Oncological Diseases

Journey of TRAIL from bench to bedside and its potential role in immuno-oncology

The role of the TNF receptors and apoptosis inducing ligands in tumor growth

Contact Info

Product

Resources

About